Breaking News, Latest News, World News, India News, Cricket, Videos & Photos

Know answers to every question related to Covid-19 vaccine from AIIMS director Randeep Guleria

After approving two vaccines of Covid-19 by the Drugs Regulator of India (DCGI), many questions are being raised about the vaccine of Bharat Biotech which is made in India. The question raised by is the 1st and 2nd phase trial data is released but the 3rd phase trial is still going on, then how the vaccine got approval for emergency use? Amid all these questions, AIIMS director Randeep Guleria answered every question carefully.

People will get vaccinated quickly

Randeep Guleria said that most of the trial data of the Oxford vaccine which has been prepared by the Serum Institute in India are from outside the country. India’s trial data is low. Similarly, all the data of Bharat Biotech is of the country. He said that the data of Phase-1 and Phase-2 of Bharat Biotech has received and the vaccine has yielded better results. Whereas, it will take 4 to 6 weeks to get the data for the third phase of the trial.

Vaccination of people in clinical mode

Guleria said that since we want to get rid of the epidemic as soon as possible. Therefore, this emergency approval has been given. It is completely safe. He said that it has been said from the regulator that whenever the vaccine is given, it will be given in clinical trial mode. The matter of concern is the increase in cases in the UK, Europe, where the lockdown has been imposed again. If more people are vaccinated, then new cases of coronavirus can be reduced. Therefore, we should be proactive in these things, so that people’s lives can be normal.

Guleria said – Avoid misinformation

Randeep Guleria further said – The company will monitor vaccination regularly. We do not have an idea of how long this vaccine will give immunity. People who will be vaccinated will be followed up by us to check how long the effect of vaccine remains. 

He said,” You can save your relatives by vaccination and no need to fear there won’t be any side effects of the vaccine. Significantly, on 1 January, Oxford’s Covishield was approved by the expert panel and recommended to the DCGI for a final decision. After that, on January 2, the expert panel had also approved Bharat Biotech’s Covaxin and recommended it to DCGI for a final decision. On 3 January, DCGI approved the emergency use of both vaccines.